Pharmaceutics (Aug 2022)

Non-Invasive Physical Plasma for Preventing Radiation Dermatitis in Breast Cancer: A First-In-Human Feasibility Study

  • Cas Stefaan Dejonckheere,
  • Adriana Torres-Crigna,
  • Julian Philipp Layer,
  • Katharina Layer,
  • Shari Wiegreffe,
  • Gustavo Renato Sarria,
  • Davide Scafa,
  • David Koch,
  • Christina Leitzen,
  • Mümtaz Ali Köksal,
  • Thomas Müdder,
  • Alina Abramian,
  • Christina Kaiser,
  • Andree Faridi,
  • Matthias Bernhard Stope,
  • Alexander Mustea,
  • Frank Anton Giordano,
  • Leonard Christopher Schmeel

DOI
https://doi.org/10.3390/pharmaceutics14091767
Journal volume & issue
Vol. 14, no. 9
p. 1767

Abstract

Read online

Radiation dermatitis (RD) is the most common acute side effect of breast irradiation. More than a century following the therapeutic utilisation of X-rays, potent preventative and therapeutic options are still lacking. Non-invasive physical plasma (NIPP) is an emerging approach towards treatment of various dermatological disorders. In this study, we sought to determine the safety and feasibility of a NIPP device on RD. Thirty patients undergoing hypofractionated whole-breast irradiation were included. Parallel to radiation treatment, the irradiated breast was treated with NIPP with different application regimens. RD was assessed during and after NIPP/radiation, using clinician- and patient-reported outcomes. Additionally, safety and feasibility features were recorded. None of the patients was prescribed topical corticosteroids and none considered the treatment to be unpleasant. RD was less frequent and milder in comparison with standard skin care. Neither NIPP-related adverse events nor side effects were reported. This proven safety and feasibility profile of a topical NIPP device in the prevention and treatment of RD will be used as the framework for a larger intrapatient-randomised double-blind placebo-controlled trial, using objective and patient-reported outcome measures as an endpoint.

Keywords